ESPR Earnings

ESPR reported its FY2025Q4 earnings on 2026-03-10, showcasing a revenue of against an estimate of 160.58M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.23 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ESPR's FY2025Q4 earnings announcement on 2026-03-10, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, ESPR's stock price tends to shift by an average of -4.38% in the 10 days leading up to earnings and 0.77% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate ESPR's annual revenue to reach 164.70M, while the EPS is projected at 0.28. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ESPR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ESPR's stock price typically moves by -4.38% in the 10 days before its earnings and 0.77% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.28 and revenue of 164.70M.

The earnings call summary reveals strong financial performance with increased royalty revenue and improved coverage approval rates, suggesting growing market confidence. The Q&A section supports this with positive feedback on guideline changes and future growth strategies. Despite flat U.S. revenues, the company has initiatives to drive future growth. The anticipated profitability by Q1 2026, coupled with the strong ESC guidelines reception, further supports a positive outlook. However, the lack of guidance for 2026 introduces some uncertainty, preventing a 'Strong positive' rating.